Current treatment options for colorectal cancer peritoneal carcinomatosis——the inspiration from the 8th edition of AJCC cancer staging system

doi:10.3877/cma.j.issn.2095-3224.2018.01.004

Abstract

Abstract:

Peritoneum is one of the common site of colorectal cancer metastasis and associated with a poor prognosis. The 8 th edition of AJCC cancer staging system has updated the M staging. Peritoneal carcinomatosis metastasis to visceral organs is designated as M1c. It is important to pay attention to the peritoneal metastasis which takes heavy burden on healthy cost. Great progress has been made in the area of the clinical presentation and mechanisms of disease progression. The aim of our study is to provide the current status of the diagnosis and treatment of peritoneal carcinomatosis.

Key words: Colorectal neoplasms, Therapy, AJCC cancer staging, Peritoneal metastasis

Chun Song, Shun Zhang. Current treatment options for colorectal cancer peritoneal carcinomatosis——the inspiration from the 8th edition of AJCC cancer staging system[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2018, 07(01): 16-20.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2018.01.004

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2018/V07/I01/16

Figures/Tables 1

References 28

[1]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2]	Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017 [J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[3]	Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study [J]. Int J Cancer, 2011, 128(11): 2717-2725.
[4]	Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer [J]. Br J Surg, 2012, 99(5): 699-705.
[5]	Aoyagi T, Terracina KP, Raza A, et al. Current treatment options for colon cancer peritoneal carcinomatosis [J]. World J Gastroenterol, 2014, 20(35): 12493-12500.
[6]	Mo S, Cai G. Multidisciplinary Treatment for Colorectal Peritoneal Metastases: Review of the Literature [J]. Gastroenterol Res Pract, 2016, 2016: 1516259.
[7]	Amin Mahul B., Edge Stephen B., Frederick L, et al. AJCC Cancer Staging Manual[S]. Springer, 2017.
[8]	姚宏伟，吴鸿伟，刘荫华. 从传统"群体化"诊治到精准"个体化"医疗：AJCC第八版结直肠癌分期系统更新解读 [J]. 中华外科杂志, 2017, 55(1): 24-27.
[9]	Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841 [J]. J Clin Oncol, 2012, 30(3): 263-267.
[10]	孙立峰，童舟，丁克峰. 外科肿瘤细胞减灭术联合腹腔内热灌注化疗--结直肠癌腹膜转移治疗的突破方向? [J]. 中华结直肠疾病电子杂志 2015, 4(1): 11-16.
[11]	Watanabe T, Itabashi M, Shimada Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer [J]. Int J Clin Oncol, 2012, 17(1): 1-29.
[12]	Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis [J]. Cancer Treat Res, 1996, 82: 359-374.
[13]	Goere D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? [J]. Ann Surg, 2013, 257(6): 1065-1071.
[14]	Esquivel J, Lowy AM, Markman M, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1, 013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis [J]. Ann Surg Oncol, 2014, 21(13): 4195-4201.
[15]	李雁，周云峰，梁寒, 等. 细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识 [J]. 中国肿瘤临床, 2015, 42(4): 198-206.
[16]	Sugarbaker PH, Mora JT, Carmignani P, et al. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy [J]. Oncologist, 2005, 10(2): 112-122.
[17]	Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures [J]. Ann Surg Oncol, 2003, 10(2): 863-869.
[18]	Turaga K, Levine E, Barone R, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States [J]. Ann Surg Oncol, 2014, 21(5): 1501-1505.
[19]	Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin [J]. J Clin Oncol, 2009, 27(5): 681-685.
[20]	Ihemelandu CU, Shen P, Stewart JH, et al. Management of peritoneal carcinomatosis from colorectal cancer [J]. Semin Oncol, 2011, 38(4): 568-575.
[21]	Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer [J]. J Clin Oncol, 2003, 21(20): 3737-3743.
[22]	Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer [J]. Ann Surg Oncol, 2008, 15(9): 2426-2432.
[23]	Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer [J]. Ann Oncol, 2016, 27(8): 1386-1422.
[24]	Klaver CE, Groenen H, Morton DG, et al. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines [J]. Colorectal Dis, 2017, 19(3): 224-236.
[25]	Sammartino P, Sibio S, Biacchi D, et al. Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC [J]. Gastroenterol Res Pract, 2012, 2012: 141585.
[26]	Baratti D, Kusamura S, Iusco D, et al. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases [J]. Ann Surg Oncol, 2017, 24(1): 167-175.
[27]	王展怀，孙立峰，袁瑛, 等. 腹膜转移的结肠癌患者MDT诊治二例 [J]. 中华结直肠疾病电子杂志 , 2016, 5(4): 351-354.
[28]	Sugarbaker PH. Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer [J]. World J Gastroenterol, 2014, 20(28): 9286-9291.

级别	分级标准
CC0	无肿瘤残留（R0切除）
CC1	<0.25 cm残留肿瘤组织
CC2	0.25~2.5 cm残留肿瘤组织
CC3	>2.5 cm残留肿瘤组织

级别	分级标准
CC0	无肿瘤残留（R0切除）
CC1	<0.25 cm残留肿瘤组织
CC2	0.25~2.5 cm残留肿瘤组织
CC3	>2.5 cm残留肿瘤组织

Please choose a citation manager

Content to export